...Phase IIa trial in 16 medication-refractory patients with Tourette's syndrome showing that once-daily oral THX-110 (THX-TS01...
...pain and obstructive sleep apnea, respectively. Therapix Biosciences Ltd. (NASDAQ:TRPX), Tel Aviv, Israel Product: THX-110 (THX-TS01...
...Scale (YGTSS) total tic score Status: Phase IIa data Milestone: Start Phase IIb (3Q18) Jennie Walters THX-110, THX-TS01 Therapix...

...THX-TS01 in about 18 patients. Therapix Biosciences Ltd. (Tel Aviv:THXBY; OTCQB:THXBY), Tel Aviv, Israel Product: THX-TS01...
...Tic Severity Scale (YGTSS) total tic score Status: Phase IIa started Milestone: NA Nora Weintraub Therapix Biosciences Ltd. THX-TS01...

...Thrombolytic Science began a double-blind, placebo-controlled Phase I trial to evaluate single ascending-doses of TS01 with...
...esterase inhibitor in 50-70 healthy male volunteers. Thrombolytic Science International LLC , Cambridge, Mass. Product: TS01...

...School and director of Beth Israel Deaconess Medical Center 's Vascular Research Laboratory. Thrombolytic Science's TS01...
...of thrombus-induced stroke, "you could test the combination of a thrombolytic agent, such as our TS01...

...to Alexis Wallace, president, CEO and co-founder of Thrombolytic Science. The company is thus developing TS01...
...treated with tPA. In dogs with venous or arterial thrombi, the mutant pro-urokinase component of TS01...
...p=0.016). The company plans to start a two-part Phase I trial this summer to evaluate TS01...

...the company raised $2.5 million in seed funding from the same angel investor. Thrombolytic Science's TS01...
...to start a Phase I trial in healthy volunteers mid-year, with data expected in 2H12. TS01...